| Translate This News In |
|---|
By the end of February or early March, Bharat Biotech will start trials of its indigenous Covaxin for children and young people in the 2-18 age group. After the company gets a formal nod from the Centre to conduct trials on children, the trials will start.
The coordinator for such trials, speaking to the leading portal, said that tests will be carried out for children between the ages of 2-5 years, 6 to 12 years and 12-18 years. He also reported that for such trials, a special protocol would be maintained.
The tests will take place once Bharat Biotech receives government approval at a leading children’s hospital in Nagpur.
In January, the company announced that the children’s vaccine would be ready by March 2021.
Covaxin is a completely indigenous Indian COVID-19 vaccine developed in collaboration with the National Institute of Virology and the Indian Council of Medical Research. The inactivated vaccine is developed and manufactured in the biocontainment facility of Bharat Biotech’s BSL-3 (Bio-Safety Level 3), one of its kind worldwide.
